prikaz prve stranice dokumenta Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
  Download
PDF 135.83 KB
Scientific paper - review paper
Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
Patient Related Outcome Measures, 9 (2018); 267-273. https://doi.org/10.2147/PROM.S146966
Padilla Galo, Alicia; Labor, Marina; Tiotiu, Angelica; Baiardini, Ilaria; Scichilone, Nicola; Braido, Fulvio

Institutional repository: Repository UHC Osijek

Cite this document

Padilla Galo, A., Labor, M., Tiotiu, A., Baiardini, I., Scichilone, N. & Braido, F. (2018). Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives. Patient Related Outcome Measures, 9., 267-273. doi: 10.2147/PROM.S146966

Padilla Galo, Alicia, et al. "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives." Patient Related Outcome Measures, vol. 9, 2018, pp. 267-273. https://doi.org/10.2147/PROM.S146966

Padilla Galo, Alicia, Marina Labor, Angelica Tiotiu, Ilaria Baiardini, Nicola Scichilone and Fulvio Braido. "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives." Patient Related Outcome Measures 9 (2018): 267-273. https://doi.org/10.2147/PROM.S146966

Padilla Galo, A., et al. (2018) 'Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives', Patient Related Outcome Measures, 9, pp. 267-273. doi: 10.2147/PROM.S146966

Padilla Galo A, Labor M, Tiotiu A, Baiardini I, Scichilone N, Braido F. Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives. Patient Related Outcome Measures [Internet]. 2018 [cited 2024 December 29];9:267-273. doi: 10.2147/PROM.S146966

A. Padilla Galo, M. Labor, A. Tiotiu, I. Baiardini, N. Scichilone and F. Braido, "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives", Patient Related Outcome Measures, vol. 9, pp. 267-273, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:222855. [Accessed: 29 December 2024]

Metadata
Title (english)Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
AuthorAlicia Padilla Galo
AuthorMarina Labor
MBZ: 357633
AuthorAngelica Tiotiu
AuthorIlaria Baiardini
AuthorNicola Scichilone
AuthorFulvio Braido
Author's institution(Clinical hospital center Osijek)
Author's institutionJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (english)
Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/μL or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific cluster of patients. Research data have shown that in patients who were expressing other clinical features of eosinophilic inflammation over asthma (rhinosinusitis and nasal polyposis), the clinical benefit of reslizumab was greater. Furthermore, it has also been observed that in patients with unsatisfactory response to mepolizumab, reslizumab is able to significantly improve the clinical and biological parameters. The aim of personalized medicine is to provide the right drug to the right patient at the right dose at the right moment. The biological treatments that were developed to modify specific pathological pathways not only provide us with the tools for the management of asthma patients but also clarify the biological mechanisms involved in its pathogenesis.
Keywords (english)
Languageenglish
Publication typeScientific paper - review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titlePatient Related Outcome Measures
Numberingvol. 9, pp. 267-273
e-ISSN1179-271X
DOIhttps://doi.org/10.2147/PROM.S146966
URN:NBNurn:nbn:hr:239:222855
Publication2018
Document URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103306/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2019-11-07 12:14:09